TCBP to Present at the 2024 ThinkEquity Conference in NYC
Rhea-AI Summary
TC BioPharm, a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, announced its participation in the 2024 ThinkEquity Conference in New York City. CEO Bryan Kobel will present on October 30, 2024, at the Mandarin Oriental Hotel.
Kobel plans to discuss TC BioPharm's clinical trials and recent balance sheet improvements. The ThinkEquity Conference is a prominent event showcasing emerging growth companies from various sectors worldwide.
Interested parties can contact IR@tcbiopharm.com for more information or to schedule meetings with management. TC BioPharm trades on NASDAQ under the ticker TCBP.
Positive
- None.
Negative
- None.
News Market Reaction – TCBP
On the day this news was published, TCBP gained 1.44%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Mr. Kobel plans to provide insight into the company's clinical trials as well as recent improvements to TC BioPharm's balance sheet. For more information or to schedule a meeting with management, please contact; IR@tcbiopharm.com.
The ThinkEquity Conference is a premier showcase of private and public emerging growth companies from all over the world, this conference features presentations by public and private companies across many sectors.
About ThinkEquity
ThinkEquity is a boutique investment bank created by experienced professionals who have worked together for over a decade, collectively financing over
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T-cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-to-present-at-the-2024-thinkequity-conference-in-nyc-302257052.html
SOURCE TC BioPharm
FAQ
When and where will TC BioPharm (TCBP) present at the ThinkEquity Conference?
What topics will TC BioPharm's CEO discuss at the 2024 ThinkEquity Conference?
How can investors schedule a meeting with TC BioPharm's management at the conference?
What type of therapies is TC BioPharm (TCBP) developing?
